These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21607894)

  • 41. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses.
    Xiao J; Guo Z; Guo Y; Chu F; Sun P
    Protein Eng Des Sel; 2006 Feb; 19(2):47-54. PubMed ID: 16339768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 3D-QSAR analysis of human immunodeficiency virus entry-1 inhibitors by CoMFA and CoMSIA.
    Pirhadi S; Ghasemi JB
    Eur J Med Chem; 2010 Nov; 45(11):4897-903. PubMed ID: 20810190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ligand-based modelling followed by synthetic exploration unveil novel glycogen phosphorylase inhibitory leads.
    Habash M; Taha MO
    Bioorg Med Chem; 2011 Aug; 19(16):4746-71. PubMed ID: 21788139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of pentacyclic triterpenes derivatives as potent inhibitors against glycogen phosphorylase based on 3D-QSAR studies.
    Liang Z; Zhang L; Li L; Liu J; Li H; Zhang L; Chen L; Cheng K; Zheng M; Wen X; Zhang P; Hao J; Gong Y; Zhang X; Zhu X; Chen J; Liu H; Jiang H; Luo C; Sun H
    Eur J Med Chem; 2011 Jun; 46(6):2011-21. PubMed ID: 21439694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases.
    Politi A; Durdagi S; Moutevelis-Minakakis P; Kokotos G; Papadopoulos MG; Mavromoustakos T
    Eur J Med Chem; 2009 Sep; 44(9):3703-11. PubMed ID: 19410337
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
    Hu X; Stebbins CE
    Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
    Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
    Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
    Puntambekar D; Giridhar R; Yadav MR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three-dimensional quantitative structure-activity relationship studies on novel series of benzotriazine based compounds acting as Src inhibitors using CoMFA and CoMSIA.
    Gueto C; Ruiz JL; Torres JE; Méndez J; Vivas-Reyes R
    Bioorg Med Chem; 2008 Mar; 16(5):2439-47. PubMed ID: 18065233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Docking and 3D-QSAR (quantitative structure activity relationship) studies of flavones, the potent inhibitors of p-glycoprotein targeting the nucleotide binding domain.
    Kothandan G; Gadhe CG; Madhavan T; Choi CH; Cho SJ
    Eur J Med Chem; 2011 Sep; 46(9):4078-88. PubMed ID: 21723648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
    Lee JH; Kang NS; Yoo SE
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2479-90. PubMed ID: 18314331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
    Pasha FA; Muddassar M; Neaz MM; Cho SJ
    J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
    Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
    J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors.
    Kuo CL; Assefa H; Kamath S; Brzozowski Z; Slawinski J; Saczewski F; Buolamwini JK; Neamati N
    J Med Chem; 2004 Jan; 47(2):385-99. PubMed ID: 14711310
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CoMFA and docking studies on glycogen phosphorylase a inhibitors as antidiabetic agents.
    Prathipati P; Pandey G; Saxena AK
    J Chem Inf Model; 2005; 45(1):136-45. PubMed ID: 15667139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A combined approach of docking and 3D QSAR study of beta-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
    Ashek A; Cho SJ
    Bioorg Med Chem; 2006 Mar; 14(5):1474-82. PubMed ID: 16275103
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative structure-based design: formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase.
    Pan D; Tseng Y; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(5):1591-607. PubMed ID: 14502494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors.
    Durdagi S; Mavromoustakos T; Papadopoulos MG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6283-9. PubMed ID: 18951793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
    Yuan M; Luo M; Song Y; Xu Q; Wang X; Cao Y; Bu X; Ren Y; Hu X
    Bioorg Med Chem; 2011 Feb; 19(3):1189-96. PubMed ID: 21237663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.